Peterslund N A, Esmann V, Geil J P, Petersen C M, Mogensen C E
Department of Medicine and Infectious Diseases, Marselisborg Hospital, Aarhus, Denmark.
J Antimicrob Chemother. 1987 Nov;20(5):743-51. doi: 10.1093/jac/20.5.743.
An oral pro-drug of acyclovir, 2-amino-9-(2-hydroxyethoxymethyl)-9H-purine (desciclovir) was evaluated in an open study comprising of 20 patients with herpes zoster. The clinical effects were comparable to those obtained with oral and intravenous acyclovir, even with a dosage of only 125 mg thrice daily. There was adequate absorption though considerable individual variation occurred. No effects of concomitant food intake were demonstrated. The finding of possible impaired conversion of desciclovir to acyclovir in one patient was unexplained and deserves attention in future studies. Likewise, more studies are needed to understand the occurrence of transient high peak plasma concentrations of acyclovir. Side-effects other than those already known with the use of acyclovir, namely reversible tubular damage, were not observed.
阿昔洛韦的口服前体药物2-氨基-9-(2-羟基乙氧基甲基)-9H-嘌呤（地昔洛韦）在一项包含20例带状疱疹患者的开放性研究中进行了评估。其临床效果与口服和静脉注射阿昔洛韦相当，即使每日仅服用125毫克，每日三次。尽管存在相当大的个体差异，但吸收充分。未显示食物摄入的影响。一名患者中地昔洛韦可能转化为阿昔洛韦受损的发现无法解释，值得在未来研究中关注。同样，需要更多研究来了解阿昔洛韦短暂性高血浆峰浓度的发生情况。未观察到使用阿昔洛韦已知副作用以外的其他副作用，即可逆性肾小管损伤。
